A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
CRISPR Therapeutics AG
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
A Study of CTX340 in Participants with Uncontrolled Hypertension.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 69
- sponsor
- CRISPR Therapeutics AG
- conditions
- Hypertension
- interventions
- DRUG: CTX340; DRUG: Placebo
- start date
- 2026-08-08
- start date type
- ESTIMATED
- primary completion date
- 2028-07-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07758634
- Published
- Aug 11, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07758634
- Categories
- Hypertension
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials